Tag: Nasdaq:ADXS

Enrolling strategic expansion of ADXS-503 HOT program in NSCLC to explore potential to enhance and/or restore sensitivity to checkpoint inhibitors…

PRINCETON, N.J., Dec. 22, 2020 (GLOBE NEWSWIRE) — Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development…

PRINCETON, N.J., Dec. 22, 2020 (GLOBE NEWSWIRE) — Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development…

PRINCETON, N.J., Nov. 27, 2020 (GLOBE NEWSWIRE) — Advaxis, Inc. (Nasdaq: ADXS) (the “Company”), a clinical-stage biotechnology company focused on…

PRINCETON, N.J., Nov. 24, 2020 (GLOBE NEWSWIRE) — Advaxis, Inc. (Nasdaq: ADXS) (the “Company”), a clinical-stage biotechnology company focused on…

PRINCETON, N.J., Nov. 23, 2020 (GLOBE NEWSWIRE) — Advaxis, Inc. (Nasdaq: ADXS) (the “Company”), a clinical-stage biotechnology company focused on…

Disease control rate of 67% and overall response rate of 17% in first six evaluable patients with immediate prior progression…

PRINCETON, N.J., Oct. 15, 2020 (GLOBE NEWSWIRE) — Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development…

PRINCETON, N.J., Sept. 29, 2020 (GLOBE NEWSWIRE) — Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development…

Strategic transition to Investigator sponsored IND from previously announced Advaxis sponsored IND Initiation of investigator sponsored Phase 1 study of…